News & Events

Adds two orphan respiratory drugs to its growing pipeline Austin, Texas – June 21, 2016 – Savara Pharmaceuticals, an emerging specialty pharmaceutical company focused on rare respiratory diseases, today announced that the company has acquired the assets of Serendex Pharmaceuticals adding two new programs to its pipeline. The lead product of Serendex, Molgradex®, is an inhaled form of granulocyte-macrophage colony-stimulating...
Read more
New York City – June 9, 2016 – Savara Pharmaceuticals, an emerging specialty pharmaceutical company focused on rare respiratory diseases, today announced that the company will present at the Jefferies 2016 Healthcare Conference in New York City. Scheduled for Friday, June 10, 2016 at 1:30 p.m. ET, Chief Executive Officer, Rob Neville, will present a detailed company overview followed by...
Read more
Preparation underway for Phase 3 trial of AeroVanc for MRSA lung infection in people with cystic fibrosis Austin, TX – March 1, 2016 – Savara Pharmaceuticals announced today that it has closed a $20 million Series C financing round. Preparations are underway to begin a pivotal Phase 3 clinical trial of AeroVanc, the first inhaled antibiotic being developed to address...
Read more
Trial also demonstrates strong trends in secondary clinical endpoints Austin, TX – February 23, 2015 – Savara Pharmaceuticals announced today positive topline results from its Phase 2 clinical trial of AeroVanc, the first inhaled antibiotic being developed to address the growing problem of methicillin-resistant Staphylococcus aureus (MRSA) lung infection in people with cystic fibrosis (CF). AeroVanc met the primary endpoint...
Read more
Company Completes Enrollment in Phase 2 Clinical Trial Austin, TX – October 6, 2014 – Savara Pharmaceuticals announced today that it closed a $10 million bridge financing round to support the development of AeroVanc, the first inhaled antibiotic being developed to address the growing number of methicillin-resistant Staphylococcus aureus (MRSA) lung infections in people with cystic fibrosis (CF). Previous investors...
Read more